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Abstract 
The yellow fever virus (YFV) epidemic in Brazil is the largest in decades. The recent 
discovery of YFV in Brazilian Aedes sp. mosquitos highlights a need to monitor the risk of 
re-establishment of urban YFV transmission in the Americas. We use a suite of 
epidemiological, spatial and genomic approaches to characterize YFV transmission. We 
show that the age- and sex-distribution of human cases is characteristic of sylvatic 
transmission. Analysis of YFV cases combined with genomes generated locally reveals an 
early phase of sylvatic YFV transmission and spatial expansion towards previously YFV-free 
areas, followed by a rise in viral spillover to humans in late 2016. Our results establish a 
framework for monitoring YFV transmission in real-time that will contribute to a global 
strategy to eliminate future YFV epidemics. 
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Yellow fever (YF) is responsible for 29000–60000 deaths annually in South America and 
Africa (1) and is the most severe mosquito-borne infection in the tropics (2). Despite the 
existence of an effective YF vaccine since 1937 (3), an estimated >400 million unvaccinated 
people live in areas at risk of infection (4). Yellow fever virus (YFV) is a member of the 
Flaviviridae family and classified into four genotypes: East African, West African, South 
American I, and South American II (5-9). YFV transmission occurs mainly via the “sylvatic 
cycle”, in which non-human primates (NHP) are infected by infected tree-dwelling 
mosquitoes, such as Haemagogus spp. and Sabethes spp. (10, 11). YFV transmission can also 
occur via an “urban cycle”, in which humans are infected by Aedes spp. mosquitoes that feed 
mostly on humans (12, 13). 
 
Brazil has recently experienced its largest recorded YF outbreak for decades, with 2043 
confirmed cases and 676 deaths since Dec 2016 (Supplementary Text and Fig. S1) (14). 
The last YF cases in Brazil attributed to an urban cycle were in Sena Madureira, in the 
northern state of Acre, in 1942 (15). An intensive eradication campaign eliminated Aedes 
aegypti and YF from Brazil in the 1950s (16) but the vector became re-established in the 
1970s and Aedes spp. mosquitoes are now abundant across most of Brazil (17). The 
consequences of a re-ignition of urban cycle transmission in Brazil would be serious, as an 
estimated 35 million people in areas at risk for YFV transmission in Brazil remain 
unvaccinated (4). New surveillance and analytical approaches are therefore urgently needed 
to monitor this risk in real-time.  
 
Between Dec 2016 and the end of Jun 2017 there were 777 PCR-confirmed human cases 
across 10 Brazilian states, mostly in Minas Gerais (60% of cases), followed by Espírito Santo 
(32%), Rio de Janeiro (3%) and São Paulo (3%) (18). The fatality ratio of severe YF cases 
was estimated at 33.6%, comparable to previous outbreaks (19, 20). Despite the exceptional 
magnitude and rapid expansion of the outbreak, little is known about its genomic 
epidemiology. Further, it is uncertain how the virus is spreading through space, and between 
humans and NHPs, and analytical insights into the contribution of the urban cycle to ongoing 
transmission are lacking.  
 
To characterise the 2017 YFV outbreak in Brazil, we first compare time series of confirmed 
cases in humans (n=683) and NHP (n=313) reported until October 2017 by public health 
institutes in Minas Gerais (MG), the epicentre of the outbreak (Fig. 1A and B, Fig. S2). The 
time series are strongly associated (cross-correlation coefficient=0.97; p<0.001). Both peak 
in late January 2017 and we estimate human cases lag those in NHP by 4 days (Table S1). 
NHP cases are geographically more dispersed in MG than human cases, which are more 
concentrated in Teófilo Otóni and Manhuaçu municipalities (Fig. 1D and E). Despite this, 
the number of human and NHP cases per municipality are positively correlated (Fig. 1F).  
 
To establish whether human cases are acquired in proximity to potential sources of sylvatic 
infection, we estimate the distance between the municipality of residence of each human case 
and the nearest habitat of potential transmission, determined by using the enhanced 
vegetation index (EVI) (21) (Supplementary Materials). The average minimum distance 
between areas with EVI>0.4 and the residence of confirmed human cases is only 5.3km. In 
contrast, a randomly chosen resident of MG lives on average ≥51km away from areas with 
EVI>0.4. Similarly, human YFV cases reside on average 1.7km from the nearest NHP case, 
whereas the mean minimum distance of a randomly chosen MG resident to the nearest NHP 
case is 39.1km. This is consistent with YF infection risk being greatest for people who reside 
or work in forested areas where sylvatic transmission occurs. We find that most human cases 
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(98.5%) were notified in municipalities with estimated YFV vaccination coverage above the 
80% threshold recommended by the World Health Organization (WHO). On average, human 
cases would need to travel 65km from their place of residence to reach an area where 
vaccination coverage is <80% (4). 
 
YFV was detected in Ae. albopictus mosquitoes caught in MG in Jan 2017 (22). Further, 
experiments suggest that Aedes spp. mosquitoes from southeast Brazil can transmit Brazilian 
YFV, although perhaps less effectively than vectors from elsewhere in Brazil (23, 24). It is 
therefore important to investigate whether YFV cases in MG occur where and when Aedes 
spp. vectors are active. To do so, we analysed confirmed chikungunya virus (CHIKV) cases 
from MG (Fig. 1C).  
 
CHIKV is transmitted by the urban mosquitoes Ae. aegypti and Ae. albopictus (25). There 
were 3755 confirmed CHIKV cases in MG during Jan 2015 to Oct 2017. The CHIKV 
epidemic in MG in 2017 began later and lasted longer than the YFV outbreak (Fig. 1C), 
consistent with the hypothesis that YFV and CHIKV in the region are transmitted by 
different vector species. However, 29 municipalities with human YFV cases also reported 
CHIKV cases (Fig. 1D and Fig. S3), indicating that YFV is indeed present in municipalities 
with Aedes mosquitoes. The mean YFV vaccination rate in districts with both YFV and 
CHIKV cases is 72.6% (range=61-78%) (4). Thus, a combination of relatively high 
vaccination rates in the locations in MG where YF spillover to humans occurs, and 
potentially lower vector competence (23, 24), may ameliorate the risk of establishment of an 
urban YFV cycle in the state. However, adjacent urban regions (including São Paulo and Rio 
de Janeiro) have lower vaccination rates (4), receive tens of millions of visitors per year (26), 
and have recently experienced many human YFV cases (20). Thus, the possibility of 
sustained urban YFV transmission in southern Brazil and beyond necessitates continual 
virological and epidemiological monitoring. 
 
We sought to establish a framework to evaluate routes of YFV transmission during an 
outbreak from the characteristics of infected individuals. Specifically, we assessed whether 
an outbreak is driven by sylvatic or urban transmission by comparing the age and sex 
distributions of observed YFV cases with those expected under an urban cycle in MG. For 
example, an individual’s risk of acquiring YFV via the sylvatic cycle depends on their 
likelihood of travel to forested areas, typically highest among male adults (27). In contrast, 
under a urban cycle, we expect more uniform exposure across age- and sex-classes, similar to 
that observed for urban cases in Paraguay (28) and Nigeria (29). 
 
The male-to-female sex ratio of reported YFV cases in MG is 5.7 (i.e., 85% of cases are 
male) and incidence is highest among males aged 40-49 (Fig. 2). We compare this 
distribution to that expected under two models of urban cycle transmission (Supplementary 
Materials). In model M1, age- and sex- classes vary in vaccination status but are equally 
exposed to YFV, a scenario that is typical of arboviral transmission (30). Under model M1, 
predicted cases are characterized by a sex ratio ~1 and incidence peaks among individuals 
aged 20-25 (Fig. 2). In model M2, we assume that the pattern of YFV exposure among age- 
and sex- classes follows that observed for CHIKV. The sex ratio of reported CHIKV cases in 
MG is 0.49 (33% of cases are male; Fig. S4). Under model M2, predicted incidence is 
highest in females aged >30. The discrepancy between the observed distribution and that 
predicted under the two urban cycle models indicates that the YF epidemic in MG is 
dominated by sylvatic transmission. This method shows that age- and sex-structured 
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epidemiological data can be used to qualitatively evaluate the mode of YFV transmission 
during an outbreak.  
 
During a YF outbreak it is important to undertake virological surveillance to (i) track 
epidemic origins and transmission hotspots, (ii) characterise genetic diversity to aid 
molecular diagnostics, (iii) detect viral mutations associated with disease severity, and (iv) 
exclude the possibility that human cases are caused by vaccine reversion.  
 
We generated 62 complete YF genomes from infected humans (n=33) and non-human 
primates (NHP) (n=29) from the most affected Brazilian states, including Minas Gerais 
(n=51), Espírito Santo (n=8), Rio de Janeiro (n=2), and Bahia (n=1) (Fig. 3, Table S3). We 
also report two new genomes from samples collected in 2003 during a previous YFV 
outbreak in MG, in 2002–2003 (31). Genomes were generated in Brazil using a combination 
of methods (Table S3); half were generated in Minas Gerais using a MinION portable YFV 
sequencing protocol adapted from (32) (Tables S4 and S5). This protocol was made publicly 
available in May 2017 following pilot sequencing experiments using a cultured vaccine strain 
(Supplementary Materials). Median genome coverages were similar for samples obtained 
from NHP (99%; median Ct=11) and from human cases (99%; median Ct=16) (Tables S5 
and S6). 
 
To put the newly generated YFV genomes in a global context, we added our genomes to 61 
publicly available genomes (33, 34). We developed and applied an automated online 
phylogenetic tool to identify and classify YFV gene sequences (also publicly available, see 
Supplementary Materials). Phylogenies estimated this tool, and using maximum likelihood 
and Bayesian methods, consistently place the Brazilian outbreak strains in a single clade 
within the South America I (SA1) genotype with maximum statistical support 
(bootstrap=100%; posterior probability>0.99) (Fig. 3A; Fig. S5).  
 
The outgroup to the outbreak clade is strain BeH655417, a human case sampled in Alto 
Alegre, Roraima, north Brazil, in 2002. In contrast, local isolates sampled during the previous 
outbreak in MG in 2003 are more distantly related to the outbreak clade within the SA1 
genotype (Fig. 3). Thus the 2017 outbreak was more likely caused by a YFV strain 
introduced from an endemic area, possibly northern or center-west Brazil (35), than by the re-
emergence of a lineage that had persisted in MG. Although low sampling densities mean this 
conclusion is provisional, similar scenarios have been suggested for previous Brazilian 
epizootics (36). The 14-year gap between the current outbreak and the date of the most 
closely related non-outbreak strain agrees with the reported periodicity of YF outbreaks in 
northern Brazil (37), thought to be dictated by vector abundance and the accumulation of 
susceptible NHP hosts (19, 38).  
 
At least 7 PCR-confirmed YFV human cases from MG received a YF vaccine ≥3 days before 
onset of symptoms. To test that these infections were caused by natural infection, and not by 
vaccine reactivation, we sequenced the YFV genomes of three of these cases (Fig. 3A, Table 
S3). Our phylogenetic analysis clearly shows that these represent natural infections caused by 
the ongoing outbreak, and are conclusively not derived from the 17DD vaccine strain (which 
belongs to the West African YFV genotype; Fig. 3A and Fig S6).  
 
Viral genomes are a valuable source of information about epidemic dynamics (e.g. (39)) but 
are rarely used to investigate specific YFV outbreaks in detail. Here we show how a suite of 
three analytical approaches, which combine genetic, epidemiological and spatial data, can 
provide insights into YFV transmission. 
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First, we used a Bayesian method (40) to explore potential covariates of fluctuations in the 
effective population size of the YFV outbreak in 2017. After confirming that genetic 
divergence in the outbreak clade accumulates over the timescale of sampling (Fig. 3B, Fig. 
S6), we tested which epidemiological time series best describe trends in inferred YFV 
effective population size. We find that effective population size fluctuations of the YFV 
outbreak are well explained by the dynamics of both human and NHP YFV cases (inclusion 
probability=0.37 for human cases and =0.63 for NHP cases) (Table S8). These two YFV 
time series explain the genetic diversity dynamics of the ongoing outbreak 103 times better 
than CHIKV incidence (inclusion probability <0.001), which represents transmission by 
Aedes spp. vectors. One benefit of this approach is that epidemiological data contribute to 
estimation of the outbreak timescale. By incorporating YFV incidence data into evolutionary 
inference, we estimate the time of the most recent common ancestor (TMRCA) of the 
outbreak clade to be late-Jul 2016 (95% Bayesian Credible Interval, BCI: Mar-Nov 2016) 
(Fig. 3C, Fig. S7), consistent with the date of the first PCR-confirmed case of YFV in NHP 
in MG (Jul 2016). The uncertainty around the TMRCA estimate is reduced by 30% when 
epidemiological and genomic data are combined, compared to genetic data alone (Fig. 3C). 
 
Second, in order to better understand YFV transmission between humans and NHP we 
measured the movement of YFV lineages between the NHP reservoir and humans, using a 
phylogenetic structured coalescent model (41). Although previous studies have confirmed 
that YFV is circulating in five neotropical NHP families (Aotidae, Atelidae, Callitrichidae, 
Pitheciidae, Cebidae; Fig 4A), thus far NHP YFV genomes during the 2017 outbreak have 
been recovered only from Alouatta spp. (family Cebidae) (33). In this analysis we used the 
TMRCA estimate obtained above (Fig. 3C) to inform the phylogenetic timescale (Fig 4B). 
All internal nodes in the outbreak phylogeny whose host state is well supported (posterior 
probability >0.8) are inferred to belong to the NHP population, consistent with an absence of 
urban transmission and in agreement with the large number of NHP cases reported in 
southeast Brazil (20). Despite this, we argue that hypotheses of human-to-human 
transmission linkage should not be tested directly using phylogenetic data alone, due to the 
large undersampling of NHP infections. Notably, the structured coalescent approach reveals 
significant changes in the frequency of NHP-to-human host transitions through time, rising 
from zero around Nov 2016 and peaking in Feb 2017 (Fig. 4C). Remarkably, this 
phylogenetic trend matches the time series of confirmed YFV cases in MG (Figs. 1A,B), 
demonstrating that viral genomes, when analysed using appropriate models, can be used to 
quantitatively track the dynamics of zoonosis during the course of an outbreak (42). 
 
Third, we measured the outbreak’s spatial spread using a phylogenetic relaxed random walk 
approach (43) (Supplementary Materials; Table S9). When projected through space and 
time (Figs. 4D-E; Movie S1), the phylogeny shows a southerly dissemination of virus 
lineages from their inferred origin in MG towards densely populated areas, including Rio de 
Janeiro and São Paulo (where YF vaccination was not recommended until Jul 2017 and Jan 
2018, respectively). We estimate virus lineages move on average 4.25 km/day (95% BCI: 
2.64 to 10.76 km/day) (44). This velocity is similar when human YFV terminal branches are 
removed (5.3 km/day) and therefore most likely reflects YFV lineage movement within the 
sylvatic cycle and not the movement of asymptomatic infected humans. These rates are 
higher than expected given the distances typically travelled by NHPs in the region (45), and 
suggest the possibility YFV lineage movement may have been aided by human activity, e.g. 
transport of infected mosquitoes in vehicles (46) or hunting or illegal trade of NHPs in the 
Atlantic forest (47, 48). The epidemic wavefront (maximum distance of phylogeny branches 
from the inferred epidemic origin) expanded steadily between Aug 2016 and Feb 2017 at an 
estimated rate of  ~3.3 km/day. Therefore by the time YF was declared a public health 
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emergency in MG (13 Jan 2017; dashed lines in Figs. 4B-D), the epidemic had already 
expanded ~600km (Fig. 4D) and caused >100 cases in both humans and NHP (Fig. 1). 
Notably, the first detection in humans in Dec 2016 was concomitant with the outbreak’s 
spatial expansion phase (Fig. 4D) and the rise in estimated NHP-to-human zoonoses (Fig. 
4C); both were likely driven by an increase in the abundance of sylvatic vectors. Thus the 
outbreak lineage appeared to circulate among NHP in a widening geographic area for several 
months before human cases were detected.  
 
Epidemiological and genomic surveillance of human and animal populations at risk is crucial 
for the early detection and rapid containment of YFV transmission. The YFV epidemic in 
Brazil continues to unfold with an increase in cases since December 2017. Longitudinal 
studies of NHP are needed to understand how YFV lineages disseminate across South 
America between outbreaks, and how epizootics are determined by the dynamics of 
susceptible animals in the reservoir. To achieve the WHO’s goal to eliminate yellow fever 
epidemics by 2026, YF surveillance demands a global, coordinated strategy. Our results and 
analyses show that rapid genomic surveillance of YFV, when integrated with epidemiological 
and spatial data, could help anticipate the risk of human YFV exposure through space and 
time and monitor the likelihood of sylvatic versus urban transmission. We hope that the 
toolkit introduced here will prove useful in guiding yellow fever control in a resource-
efficient manner. 
 
 
 
 
Acknowledgements 
We thank FUNED-MG and the Brazilian YFV surveillance network for their essential 
contributions. N.R.F. thanks J. F. Drexler for sharing data and N. Trovão for discussions. 
We thank Oxford Nanopore Technologies for technical support. L.C.J.A. thanks QIAGEN 
for reagents and equipment. This work supported in part by CNPq # 400354/2016-0 and 
FAPESP # 2016/01735-2. N.R.F. is supported by a Sir Henry Dale Fellowship 
(204311/Z/16/Z), internal GCRF grant 005073, and John Fell Research Fund Grant 005166. 
This research received funding from the ERC (grant agreement 614725-PATHPHYLODYN) 
and from the Oxford Martin School. MUGK acknowledges funding from a Branco Weiss 
Fellowship, administered by ETH Zurich, a Training Grant from the National Institute of 
Child Health and Human Development (T32HD040128) and the National Library of 
Medicine of the National Institutes of Health (R01LM010812, R01LM011965). SD is funded 
by the Fonds Wetenschappelijk Onderzoek (FWO, Flanders, Belgium). GB acknowledges 
support from the Interne Fondsen KU Leuven / Internal Funds KU Leuven. ACdC is funded 
by FAPESP # 2017/00021-9. ACdC and ECS thank Illumina, Zymo Research, Sage Science 
and Promega for donation of reagents. BBN and SC are supported by the EU’s Horizon 2020 
Programme through ZIKAlliance (grant 734548), the Investissement d’Avenir program, the 
Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases program 
(grant ANR-10-LABX-62-IBEID), the Models of Infectious Disease Agent Study of the 
National Institute of General Medical Sciences, the AXA Research Fund, and the Association 
Robert Debré. PL and MAS acknowledge funding from the European Research Council 
(grant agreement 725422-ReservoirDOCS) and from the Wellcome Trust Collaborative 
Award 206298/Z/17/Z. PL acknowledges support from the Research Foundation, Flanders 
(Fonds voor Wetenschappelijk Onderzoek, Vlaanderen, G066215N, G0D5117N and 
G0B9317N).  
 
 9 
Author contributions 
N.R.F., L.C.J.A., S.C.H., A.M.B.F., M.U.G.K., S.C., and O.G.P. designed the study. 
S.C.H., J.J.G., R.S.de A., F.C.M.I., J.X., R.D.O.C., J.T., M.G., L.C.J.A. and N.R.F., 
undertook fieldwork. S.C.H., J.Q., J.J.G., A.C.da C., S.C.V.K., V.F., de O.T. undertook 
experiments. N.R.F., L. du P., J.T., S.D., G.B., O.G.P., C.-H.W., T.I.V. and P.L. 
performed genetic analyses. M.U.G.K., S.C., S.F., J.L, U.O., L.A., D.Y. and N.R.F. 
performed epidemiological and cartographic analyses. B.N., F.M.S. and N.R.F. performed 
historical YFV review. N.R.F., M.U.G.K., L.C.J.A., S.C. and O.G.P. wrote the manuscript. 
E.C.S, J.T., L. du P., R.P.S., P.L., de A.C.F.C., R.S.de A., A.M.B.F. edited the manuscript. 
All other authors were involved in collection, processing, sequencing and bioinformatics 
of samples and geographic data. All authors read and approved the contents of the 
manuscript. 
 
Competing interests 
N.J.L. and L.C.J.A. received free-of-charge reagents in support of the project from Oxford 
Nanopore Technologies.  
 
Data and materials availability 
Raw data, code, and analysis files are available on GitHub repository 
(https://github.com/arbospread/YFV-monitoring). See https://github.com/zibraproject/zika-
pipeline/tree/master/schemes for MinION sequencing protocols. Genome sequences 
generated here are available under GenBank accession numbers MH018064-MH018115 and 
MH484423-MH484434. 
  
 10 
Figure 1 
 
 
 
 
 
 
Fig. 1. Spatial and temporal epidemiology of YFV and CHIKV in Minas 
Gerais, MG. (A) Time series of human YFV cases in MG (676 cases across 
61 municipalities) confirmed by serology, RT-qPCR or virus isolation during 
the first YFV epidemic wave (Aug 2016 to Oct 2017). (B) Same as panel A, 
but showing NHP YFV cases (313 cases across 90 municipalities), confirmed 
by RT-qPCR. (C) Same as panel A, but for human CHIKV cases (3668 cases 
across 129 municipalities). (D) Geographic distribution of human YFV cases 
in MG. (E) Geographic distribution of NHP YFV cases in MG. Fig. S2 
shows the corresponding geographic distribution of CHIKV cases. (F) 
Association between the number of human and NHP cases in each 
municipality of MG (Pearson’s r=0.62; p<0.0001; non-parametric 
Spearman’s rank ρ=0.32; p<0.05).  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Age and sex distribution of YFV cases in Minas Gerais, 2016-
2017. Red bars show the proportion of observed YFV cases in Minas Gerais 
that occur in each age class, in (A) males and (B) females. These empirical 
distributions are different from those predicted under two models of urban 
cycle transmission (M1 = white bars and M2 = orange bars; see text for 
details). 
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Figure 3 
 
 
 
 
Fig. 3. Molecular phylogenetics of the Brazilian YFV epidemic. (A) 
Maximum likelihood phylogeny of complete YFV genomes showing the 
outbreak clade (red triangle) within the SA1 genotype (see Figs. 4 and S6 for 
details). SA2, WAfr and EAfr indicate the South America II, West African, 
and East Africa genotypes, respectively. For clarity, five YFV strains 
introduced to Venezuela from Brazil (49) are not shown. The scale bar is in 
units of substitutions per site (s/s). Node labels indicate bootstrap support 
values. RO 2002 = strain BeH655417 from Roraima. MG 2003 = two strains 
from the previous YF outbreak in MG in 2003. 17DD = the vaccine strain 
used in Brazil. AO 2016 = YFV outbreak Angola in 2015-2016 (13). (B) 
Root-to-tip regression of sequence sampling date against genetic divergence 
from the root of the outbreak clade (see Fig. S6A). Sequences are coloured by 
sampling location. (C) Violin plots showing estimated posterior distributions 
(white circle=mean) of the time of the most common ancestor (TMRCA) of 
the outbreak clade. Estimates were obtained using two different datasets 
(grey=SA1 genotype, red=outbreak clade) and under different evolutionary 
models: a=uncorrelated lognormal relaxed clock (UCLN) model with a 
skygrid tree prior with covariates (specifically, the time series data shown in 
Figs. 1A-C; see Fig. S7); b=UCLN model with a skygrid tree prior without 
covariates; c=fixed local clock model (see Supplementary Materials). 
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Figure 4 
 
 
 
Fig. 4. Spatial and evolutionary dynamics of YFV outbreak. (A) Frequency of 
detection of YFV in non-human primates in the Americas (50). Circle sizes represent 
the proportion of published studies (n=15) that have detected YFV in each primate 
family and region. SA=South America (except Brazil), CA=Central America, 
CB=Caribbean, BR1=Brazil (before 2017), BR2=Brazil (this study). (B) Maximum 
clade credibility phylogeny inferred under a two-state (human and NHP) structured 
coalescent model. External node symbols denote sample type. Grey bars and labels 
to the indicate sample location (RJ=Rio de Janeiro, ES=Espírito Santo, BA=Bahia, 
others were sampled in MG). Internal nodes whose posterior state probabilities are 
>0.8 are annotated by circles. Node labels indicate posterior state probabilities for 
selected nodes. Internal branches are coloured blue for NHP, red for human. Fig. S8 
shows a fully annotated tree. (C). The average number of YFV phylogenetic state 
transitions (from NHP to human) per month. Solid line=median estimate. Shaded 
area=95% BCI. (D) Expansion of the YFV epidemic wavefront estimated using a 
continuous phylogeographic approach (35). At each timepoint the plot shows the 
maximum spatial distance between phylogeny branches and the inferred location of 
outbreak origin. Solid line = median estimate. Shaded area = 95% BCI. (E) 
Reconstructed spatiotemporal diffusion of the YFV outbreak. Phylogeny branches 
are arranged in space according the locations of phylogeny nodes (circles). Locations 
of external nodes are known, whilst those of internal nodes are inferred (44). 
DF=Distrito Federal, GO=Goiás, SP=São Paulo. Shaded regions show 95% credible 
regions of internal nodes. Nodes and uncertainty regions are coloured according to 
time.  
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Supplementary Text 
 
Brief overview of YFV in Brazil and YFV urban outbreaks 
In the Americas, the YFV jungle/sylvatic cycle involves virus transmission between 
jungle/sylvatic mosquitos and non-human primates (NHP). In contrast, an urban YFV 
transmission cycle (sometimes called the domestic cycle) involves virus transmission 
between humans by Ae. aegypti mosquitoes; a secondary role of Ae. albopictus in YFV urban 
epidemics remains controversial (22-24, 51, 52). 
 
Several large urban YFV outbreaks have been reported in Brazil since the 17th century, 
in the states of Pernambuco (Recife, 1685), Bahia (1686-1692), Bahia (Salvador, 1849) and 
Rio de Janeiro (1849-1908) [reviewed in (14)]. After an absence of 20 years, YFV re-
emerged in Rio de Janeiro (1928-1929) causing a recorded 738 cases and 478 deaths (14). 
This was the last large urban outbreak in the Americas. The last 3 suspected urban YFV cases 
were reported in Brazil in 1942, in the state of Acre, Sena Madureira municipality, in 
northern Brazil (15). In 1932, Soper et al. identified sylvatic YFV transmission in Vale do 
Canaã, Espírito Santo state, in southeast Brazil (53). Shortly thereafter, in 1937, Theiler & 
Smith developed the 17D YFV vaccine (54) and in the same year a field vaccine trial started 
in Brazil. In 1955 Brazil reported the elimination of the Ae. aegypti vector in the country 
through a national campaign using the insecticide dichloro-diphenyl-trichloroethane (DDT) 
(15). By 1970 Ae. aegypti had been eradicated from most of Latin America (55). 
 
After an estimated 30 years, Ae. aegypti was re-introduced multiple times to Brazil (56) 
and the vector is now well-established in all municipalities of the country (17). Between 1950 
to 2016 there were 1366 YFV cases in total across the country, linked to the sylvatic 
transmission cycle (Fig. S1). 
 
Vectors involved in sylvatic YFV transmission in Brazil include mosquitos of the genera 
Haemagogus and Sabethes, especially Hg. janthinomys, Hg. albomaculatus, Hg. 
leucocelaenus, Sa. Soperdi, Sa. chloropterus, Sa. Cyaneus, and Aedes serratus (11, 57-60). 
Countrywide statistics from Brazil during 2000-2012 indicate that ~86% of sylvatic cases of 
YFV in humans occur in adult males. They acquire the infection in forested areas and 
typically have occupations such as agricultural workers, tourists, fishermen, students and 
truck drivers (19, 61). A high proportion of male YFV cases (76%) was observed in a large 
epidemic of sylvatic YFV in Peru in 1997 (62).  
 
Urban yellow fever epidemics have been reported in several African countries and 
regions, including Nigeria-Lagos (1925-26), Ghana-Accra (1926-27 and 1937) and Gambia-
Banjul (1937), Nigeria-Jos (1969), Angola-Luanda (1971), Nigeria-Azare et Bauchi (1979), 
Nigeria-Sud Ouest (1987), Angola-Luanda (1988), Nigeria-etat de Delta (1995), Nigeria-
Kano (2000), Côte d’Ivoire-Abidjan (2001), Guinea-Conakry (2002), Dakar and Touba-
Senegal (2002), Bob-Dioulasso-Burkina Faso (2004), and Luanda-Angola (2017) (62, 63). A 
large urban outbreak of YFV in western Nigeria in 1987-1988 exhibited a male:female case 
ratio of 1.4:1, with 71% of cases being <20 years old (29). However direct comparisons of 
YF epidemiological profiles between outbreaks in South America and Africa are not possible 
due to several factors including (i) strong heterogeneity in vaccination rates (4), (ii) different 
demographic profiles in each region, (iii) the presence of different YFV genotypes in each 
region (36, 64, 65) and (iv) the presence of other infections, such as hepatitis B, C, or E, that 
may confound case reporting (66).  
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In the Americas, evidence of urban YF transmission is more limited. Serology indicated 
a small YFV outbreak in the Department of Santa Cruz, Bolivia, in 1999 (67). However, of 
the 6 confirmed cases (all male), four had travelled outside the city. During 2008-2009, 28 
human YFV cases in Paraguay were reported (28). Of these, 19 were notified in the 
departments of San Pedro and Caaguazú and were considered to be sylvatic cases (based on 
the travel history and occupation of infected patients). The remaining 9 cases occurred in an 
urban area of the Central Department, Municipio of San Lorenz, and lived <500m from each 
other: 4 were housewives, 4 were students, and 1 was a dependent. None had travelled during 
the two weeks prior to symptom onset. The average age of these nine individuals was 25 
(range 11-39) and 44% (4/9) were male.  
 
 
Materials and Methods 
 
Description of epidemiological data from Minas Gerais, Brazil 
The 853 municipalities in Minas Gerais are distributed among 28 regional health 
facilities (Gerências Regionais de Saúde). Local zoonotic surveillance units collected tissue 
samples from carcasses of NHPs, following the guidelines for epizootic surveillance of YFV 
(36). NHP samples were sent to Fundação Ezequiel Dias (FUNED), Flavivirus Reference 
Laboratory of the Brazilian Ministry of Health in Oswaldo Cruz Foundation of Rio de 
Janeiro, and Universidade Federal Minas Gerais for molecular diagnostics. For NHP samples, 
associated metadata (e.g. primate family, genus or species, date of capture, municipality of 
sample collection) were obtained directly from local teams or from the National Reportable 
Disease Information System - SINAN (Sistema de Informação de Agravos de Notificação; 
http://portalsinan.saude.gov.br/). To detect viral RNA in YFV suspected cases, post-mortem 
liver NHP samples were tested using YFV RT-qPCR.  
 
For human cases, hospitals or health centers report cases and collect blood/serum 
samples or tissue samples (fatal cases only). For each tested case, metadata was retrieved 
from SINAN. Between Jan 2015 and Sep 2017, 2571 samples from patients residing in 212 
municipalities of Minas Gerais (MG) with symptoms compatible with YFV infection were 
tested at (FUNED), located in Belo Horizonte, MG, southeast Brazil (Fig. S2), and the 
Flavivirus Reference Laboratory of the Brazilian Ministry of Health in Oswaldo Cruz 
Foundation of Rio de Janeiro, in Rio de Janeiro. During the same period, 9555 human 
samples from patients residing in 362 municipalities of MG were tested for CHIKV infection 
in the same laboratories (Fig. S2) following standard procedures (68). Although human and 
NHP cases are reported via different mechanisms, it is difficult to exclude the possibility that 
reporting variation among municipalities may play some role in the spatial association of 
cases. Following Pan American World Health Organization (PAHO) guidelines, YFV human 
samples were obtained ≤ 6 days after the onset of clinical symptoms, after which they were 
subjected to RT-qPCR. If samples were obtained >6 days after onset of disease, serological 
confirmation of YFV through IgM detection was performed. Due to potential cross-reactivity 
of serological assays, a positive YF serological test performed 6 days after onset of symptoms 
can indicate one of (i) recent YF infection, (ii) past YF vaccination, or (iii) infection with 
other circulating flaviviruses, such as Zika virus or dengue virus (69). Sex, age, municipality 
of residence, date of sample collection, and date of onset of symptoms were available for 
human YFV cases, YFV(H). 
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From the cases tested in MG between Jan 2015 and October 2017, the following datasets 
were prepared. Note that the same patient may have been tested with different tests, so the 
sample size (N) given below equals the total number of individuals with at least one positive 
test, which may be less than the sum of the number of positive tests:  
 
 Dataset A: YFV(H) cases confirmed either by RT-qPCR (n=159) or by virus isolation 
(n = 62) or by IgM (n=478) at FUNED (n=683);  
 Dataset B: YFV(NHP) cases confirmed by RT-qPCR in liver tissue analysed at the 
UFMG (N=314);  
 Dataset C: CHIKV confirmed by RT-qPCR (n=144) or by IgM (n=3609) at FUNED 
(N=3755; no virus isolation was performed for CHIKV).  
 Dataset D: YFV(H) confirmed either by RT-qPCR (n=159) or by virus isolation 
(n=62) at FUNED (n=221);  
 Dataset E: CHIKV confirmed by RT-qPCR at FUNED (n=144). 
 
The geographic distributions of YFV(H), YFV(NHP) and CHIKV cases are shown in 
Fig. 1D, Fig. 1E and Fig. S3, respectively. Note that these maps correspond, respectively, to 
datasets A, B and C described above.  
 
To assess the association between the time series of YFV(NHP) and YFV(H) cases, we 
computed pairwise cross correlations among datasets A, B, and C, correcting for time lag and 
assuming that each dataset followed a unimodal distribution across time that covered a single 
epidemic wave of YFV. The correlations and corresponding P-values are shown in Table S1. 
Note that the time series are compared at the state, not local, level, making the analysis 
comparison more robust to sampling variation among municipalities. 
 
 
Model of age-sex distributions under urban and sylvatic transmission cycles  
To investigate whether human YF cases result from an urban or sylvatic transmission 
cycle we examined the age-sex distribution of human YF cases in MG between Dec 2016 
(the date of first confirmed human YFV RT-qPCR case) and October 2017 (see Fig. 1). We 
define the “urban cycle” as YFV transmission between individuals mediated by 
anthropophilic Ae. aegypti mosquitoes. This may occur in urban, peri-urban or rural settings 
(hence the term ‘domestic cycle’ is sometimes used instead). We developed two models to 
predict the age-sex distribution of YFV cases expected under an urban cycle. In model M1, 
we assume that exposure to YFV in the urban cycle is independent of sex and age, 
approximately equivalent to the situation observed during urban YF outbreaks in Paraguay 
(28) and Nigeria (29). We reconstructed the resulting age-sex distribution from the 
underlying population age pyramid in MG (70) and from vaccine coverage per birth cohort 
(4). The expected number of individuals of age a and sex s that are at risk of YFV infection is 
then: 
 
𝑆1(𝑎, 𝑠) = 𝑁(𝑎, 𝑠). 𝑝𝑈(𝑎, 𝑠) 
 
where 𝑁(𝑎, 𝑠) is the number of individuals of age a and sex s in the population and 𝑝𝑈(𝑎, 𝑠) 
is the proportion of unvaccinated individuals in that group. We assume that the proportion of 
vaccinated individuals is independent of sex in a given birth cohort. The expected proportion 
of YFV cases that are of age a and sex s is therefore: 
 
(1) 
(2) 
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𝑃1(𝑎, 𝑠) =
𝑆1(𝑎, 𝑠)
∑ 𝑆1(𝑎′, 𝑠′)𝑎′,𝑠′
 
 
 
In model M2, we assume that, under a scenario of urban cycle transmission, the risk of 
exposure to YFV for a susceptible individual would be proportional to that seen for CHIKV 
cases (Fig. S4).  
 
Let 𝐶(𝑎, 𝑠) denote the number of reported CHIKV cases of age a and sex s. For an individual 
of age a and sex s, the relative risk of being reported as a CHIKV case is defined as: 
 
𝑅𝑅𝐶𝐻𝐼𝐾(𝑎, 𝑠) =
𝐶(𝑎, 𝑠)
𝑁(𝑎, 𝑠)
 
 
Thus in model M2, the expected proportion of YFV cases that are of age a and sex s is: 
 
𝑃2(𝑎, 𝑠) =
𝑆1(𝑎, 𝑠). 𝑅𝑅𝐶𝐻𝐼𝐾(𝑎, 𝑠)
∑ 𝑆1(𝑎′, 𝑠′)𝑎′,𝑠′ . 𝑅𝑅𝐶𝐻𝐼𝐾(𝑎′, 𝑠′)
 
 
The age-sex distribution of dengue virus cases in Minas Gerais cannot be used as a 
proxy for that YFV in an urban cycle because, in areas where dengue has been circulating for 
years, the build-up of dengue immunity in the population will skew the age distribution of 
cases towards younger age groups. Further, three immunologically-distinct serotypes of 
dengue virus (1, 2 and 3) co-circulate in the region (71) but the serotypes of reported cases 
are not always known or tested. Additionally, it is not possible to use Zika case counts as a 
proxy because Zika virus molecular diagnoses were strongly biased towards women of 
gestational age, in accordance with Ministry of Health guidelines (72).  
 
While we can propose simple and generic models to describe the expected age-sex 
distribution of cases in the YFV urban cycle, it is harder to predict what this distribution 
might look like in the sylvatic cycle because the propensity of individuals to travel to forested 
areas will likely depend on complex socio-economic and cultural factors that may exhibit 
substantial variation among regions, hence it is not feasible to construct a generic model of 
the age-sex distribution of YFV cases in the sylvatic cycle. 
 
 
Estimating expected spatial distances to the source of YF infection 
Many human YFV cases were reported in cities across the region and the travel history 
of most cases remains unknown. To assess the likelihood of a sylvatic transmission cycle 
scenario, in which most infections occur in forested areas, we calculate the average great 
circle distance between the place of residence of each human case and the nearest location 
with environmental conditions likely suitable for sylvatic transmission (73). We then 
compare this distance to that expected for typical (non-YFV infected) residents of Minas 
Gerais, estimated using high-resolution population datasets from 2015 (74). We used overall 
greenness of the environment [Enhanced Vegetation Index (EVI) (75)] to identify areas with 
environmental conditions suitable for sylvatic transmission. The EVI has been previously 
determined to be the best-fitting predictor of seasonal YFV transmission (76). Several 
thresholds of EVI for each municipality were considered: 0.33 (5%), 0.41 (50%), 0.46 (95%). 
Great-circle distances were calculated using the “rdist.earth” function in R (77). We also 
(3) 
(4) 
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calculated the distance to areas with known occurrences of positive non-human primates, 
again for both confirmed YF cases in humans and for typical residents of Minas Gerais. 
 
 
Ethical statements for biological data 
The project was supported by the Pan American World Health Organization (PAHO) 
and the Brazilian Ministry of Health as part of arboviral genomic surveillance efforts. Human 
samples were previously obtained for routine diagnostic purposes from persons visiting local 
clinics in Minas Gerais and Rio de Janeiro. Residual anonymized clinical diagnostic samples, 
with no or minimal risk to patients, were provided for research and surveillance purposes 
within the terms of Resolution 510/2016 of CONEP (Comissão Nacional de Ética em 
Pesquisa, Ministério da Saúde; National Ethical Committee for Research, Ministry of 
Health). We included 121 samples extracted at the Fundação Ezequiel Dias (FUNED), the 
main central public health laboratory in Minas Gerais (MG) (sub-study I). An additional 8 
non-human primate (NHP) samples were extracted at the Universidade Federal de Minas 
Gerais (UFMG) and subsequently sent to FIOCRUZ Bahia for sequencing (Table S2). For 
the NHP samples from UFMG, authorization was obtained by the State Health Department of 
Minas Gerais and by the Ethics Animal Research Committee of Universidade Federal de 
Minas Gerais (License CEUA: 347/2017). Human samples were also processed at the 
Reference Centre for Arbovirus in Rio de Janeiro, the Laboratory of Flavivirus at FIOCRUZ 
Rio de Janeiro (sub-study II). Ethical approval for human samples was obtained from 
CEP/CAAE: 0026.0.009.000-07, with Institutional Review Board approval numbers 
027/2007 and 1.920.256). Samples obtained from the Reference Centre for Arbovirus of São 
Paulo, Adolfo Lutz Institute (IAL) have been processed in agreement with routine 
surveillance activities from the Brazilian Ministry of Health and under the CEUA (Comitê de 
Ética de Uso de Animas em Pesquisa) registration number 02/2011. 
 
 
Viral RNA isolation and sample processing  
Human clinical samples included tissue and serum or plasma. In brief, viral RNA was 
extracted from 200 μL of clinical sample using QIAmp Viral RNA Minikit (Qiagen) 
according to the manufacturer’s instructions but with several protocol changes. Tissue 
samples were first homogenised using a TissueLyser LT (Qiagen). A small piece of tissue 
(~2 mm diameter) was cut using a disposable scalpel and added to a 2 mL Eppendorf tube 
containing a 5 mm stainless steel bead (Qiagen). 560 μl AVL lysis buffer (Qiagen) was added 
to each tube and the sample was homogenised for 5 min at 50 Hz on a TissueLyser LT 
followed by a 10 min incubation at room temperature to lyse virions. Samples were 
centrifuged at 1,200g for 2 min to pellet cellular material, and 500 μL of supernatant was 
transferred to a new tube containing 500 μL of 100% EtOH. For serum or plasma samples, 
200 μL of the sample was added to 560 μL of AVL lysis buffer (Qiagen) and left to incubate 
for 10 minutes before addition 560 μL of 100% EtOH. RNA extraction was subsequently 
completed on-site according the manufacturer’s protocol for all sample types. To avoid 
contamination between samples due to the high number of virions, regular glove changes 
were conducted and parafilm was used to seal the gap between collection tubes and QIAamp 
Mini columns (Qiagen) during centrifugation. Batches always contained only primate or only 
human samples and a negative extraction control was processed with every batch. Human 
samples were linked to a record of clinical information such as date of onset of symptoms, 
date of sample collection, municipality, state of residence, age, sex, residence type and, when 
available, vaccine and travel history. 
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Real-time quantitative PCR (sub-studies I to III) 
YFV reverse transcription quantitative real-time PCR (RT-qPCR) was performed on 121 
samples using the Superscript III Platinum One-Step qRT-PCR System (Invitrogen) on a 
StepOnePlus Real-Time PCR machine (Applied Biosystems). The conserved YFV 5’ non-
coding region was targeted using the primers YFall15F (5’ to 3’: 
GCTAATTGAGGTGYATTGGTCTGC), YFall103R (5’ to 3’: 
CTGCTAATCGCTCAAMGAACG) and the probe YFall41 (5’ to 3’: FAM- 
ATCGAGTTGCTAGGCAATAAACAC-BHQ), based on the previously described 
Domingo’s assay (78). Thermocyler conditions consisted of reverse transcription at 45ºC for 
15 min, denaturation at 95 °C for 5 min, followed by 40 cycles of denaturation at 95 °C for 
10s, and annealing and extension at 60°C for 40s. To check RNA isolation efficiency, we 
used RNase P as an endogenous positive control. Assays for RNase P used the primers 
RNaseP-F (5’ to 3’:AGATTTGGACCTGCGAGCG), RNaseP-R 
(GAGCGGCTGTCTCCACAAGT), and a probe (FAM- 
TTCTGACCTGAAGGCTCTGCGCG-BHQ1). 
 
 
Validation of the sequencing primer scheme for MinION  
Two candidate sequencing primer schemes were designed using Primal Scheme 
(http://primal.zibraproject.org) to amplify 500 bp or 1000 bp overlapping amplicons (32) of 
the complete genome of the YFV South American genotype 1, based on previous reports 
(33), with an overlap length of 75 bp between each neighbouring pair of primers (Table S4). 
The scheme was validated at Public Heath England, UK. cDNA synthesis and multiplex PCR 
were conducted on RNA extracts from a cultured vaccine strain YFV 17D. PCR products 
were cleaned using 0.8x Ampure XP (Beckman Coulter) bead cleanups, quantified, and 
pooled. Libraries for the MinION were constructed using the ligation sequencing kit 1D 
(SQK-LSK108) and native barcoding kit (EXP-NBD103). The library was sequenced on an 
R9.4 flow cell (FLO-MIN106). Basecalled reads were aligned to a YFV reference genome 
using bwa (GenBank accession number: JF912190). Given that the regions overlap, alternate 
amplicons are amplified in two separate PCR reactions. These are pooled and barcoded 
together (in previous studies (32, 79) these pools were barcoded separately, but this reduces 
the number of samples per flowcell by half). Mapping the reads to the reference genome 
showed the scheme provided good coverage across most of the coding-region of the genome. 
95% of the genome had a depth of at least 379 reads, and 70% of the genome had a depth of 
at least 1941 reads. Both the 500bp and 1000bp PCRs with 40 cycles of PCR were tested in 
May 2017 at Minas Gerais (FUNED) on 7 samples of previously extracted RNA. Following 
PCR, quantitated dsDNA concentrations were higher for the 500 bp scheme than for the 1000 
bp scheme, and therefore this scheme was chosen for all following assays 
(https://github.com/zibraproject/zika-pipeline/tree/master/schemes). 
 
 
cDNA synthesis, library preparation and sequencing for MinION (sub-study I) 
cDNA was reverse transcribed from viral RNA using the Protoscript II First Strand 
Sequencing kit (NEB) with random hexamer priming. Multiplex PCR was conducted using 
Q5 High Fidelity Hot-Start DNA Polymerase (New England Biolabs) and the 500bp 
sequencing primer scheme (Table S4). All samples were subjected to 32-40 cycles of PCR 
using the thermocycling conditions and reaction conditions described in Quick et al. (32). 
PCR products were purified using a 1x Ampure XP bead cleanup and concentrations were 
measured using a Qubit dsDNA High Sensitivity kit on a Qubit 3.0 fluorimeter 
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(ThermoFisher). Library preparation for the ONT MinION was conducted using Ligation 
Sequencing 1D (SQK-LSK108) and Native Barcoding kit (EXP-NBD103) according to the 
manufacturer’s instructions, but with the changes detailed in (32). Amplified DNA and 
appropriate negative controls were sequenced in barcoded multiplexes of 6–12 samples per 
MinION run using FLO-MIN106 flow cells. Sequencing was performed without basecalling 
for 48 hours using MinKNOW. Consensus sequences for each barcoded sample were 
generated following previously published methods (32). Briefly, raw files were basecalled 
using Albacore, demultiplexed and trimmed using Porechop, and then mapped with bwa to a 
reference genome (GenBank Accession No. JF912190). Nanopolish variant calling was 
applied to the assembly to detect single nucleotide variants to the reference genome. 
Consensus sequences were generated; non-overlapped primer binding sites, and sites for 
which coverage was <20X were replaced with ambiguity code N. Sequencing statistics can 
be found in Table S5. 
 
 
cDNA synthesis and sequencing using Ion Torrent (sub-study II) 
cDNA synthesis was executed with SuperScript III Reverse Transcriptase 
(ThermoFisher Scientific) and random hexamers. Subsequently, YFV genome amplification 
was performed using Platinum Taq High Fidelity DNA Polymerase (ThermoFisher 
Scientific). PCR products were analyzed by electrophoresis gel and purified using PureLink 
Genomic DNA spin columns (ThermoFisher Scientific). YFV amplicons were quantified 
using a Qubit dsDNA High Sensitivity kit on the Qubit Fluorometric 2.0 (ThermoFisher 
Scientific). Sequencing libraries were prepared using 100ng of PCR products with an Ion 
Plus Fragment Library Kit (ThermoFisher Scientific), according to the manufacturer's 
instructions. For template amplification, emulsion PCR (emPCR) was performed using the 
Ion PGM Template OT2 kit and the Ion OneTouch 2 system (ThermoFisher Scientific). Ion 
Sphere particles (ISPs) were enriched using the Ion OneTouch ES (ThermoFisher Scientific). 
Enriched ISPs were sequenced using the Ion Torrent Personal Genome Machine Sequencer 
and the Ion PGM Hi-Q Sequencing kit (ThermoFisher Scientific), with the Ion 316 Chip. 
Data were collected for up to 8-9h. Reads were extracted, primer trimmed and mapped to a 
reference using Geneious R9 (9.1.7 version) (80). Briefly, primers were trimmed from each 
read (first 22 nt from 5’ end). Reads were extracted based on amplicon size and coverage 
normalization was performed. Consensus genome sequences were generated by reference 
mapping to GenBank accession JF912190, and sites for which coverage was <3X were 
replaced with ambiguity code N. Sequencing statistics can be found in Table S6. 
 
 
cDNA synthesis, library preparation and sequencing using Illumina (sub-study III) 
Fourteen specimens were centrifuged at 20,000×g for 20 min and then filtered through a 
0.45 µm filter (Merck Millipore, USA). The filtrates were treated with a mixture of nuclease 
enzymes to reduce background nucleic acids from the host cells and bacteria. RQ1 RNase-
Free DNase (Promega Inc), DNase I (Zymo Research), Benzonase (Merck Millipore), RNase 
A (Zymo Research), RNase ONE (Promega Inc), Turbo DNase (Thermo Fisher) and 10X 
Turbo DNase buffer were added to the clarified supernatant and incubated at 37°C for 2h. 
Viral nucleic acids were extracted using a Maxwell 16 automated extractor (Promega Inc). 
Viral cDNA synthesis from extracted viral RNA/DNA was performed by using 50 pmol of a 
dodecamer of random primer in a reverse transcription reaction with AMV Reverse 
Transcriptase (Promega Inc) and RNasin Ribonuclease Inhibitor (Promega Inc). The 2nd 
strand cDNA synthesis was performed using DNA Polymerase I Large (Klenow) Fragment 
(Promega Inc), followed by the use of a Nextera XT Sample Preparation Kit (Illumina Inc) to 
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construct a DNA library with each sample identifiable using dual barcodes. For size 
selection, we used a Pippin Prep (Sage Science Inc) to select a 400 bp insert (range 200-600 
bp). The library was deep-sequenced using the MiSeq Illumina platform with 2 x 300 bp 
paired ends. Paired-end reads of 2x300 bp generated by MiSeq were demultiplexed using the 
vendor software from Illumina. Demultiplexed Illumina reads were mapped on the JF912190 
reference genome using bwa-mem program (81). The genome analysis toolkit (82) was used 
to perform variant calling and generate consensus sequences with a 3x minimum read depth 
coverage. Sequencing statistics can be found in Table S7. 
 
 
Automated phylogenetic typing tool  
We developed an tool that automatically classifies and accurately annotates YFV 
genome sequences, which is publicly available at 
https://www.genomedetective.com/app/typingtool/yellowfevervirus. 
 
To build this YFV typing tool, we prepared two reference datasets that include publicly 
available sequences, one with whole-genomes (n=34, length=10,235 bp) and another with 
envelope gene sequences (n=34, length=1,443 bp). The accession numbers for each reference 
sequence of each genotype are as follows are as follows; for South American genotype 1: 
JF912190, JF912187, JF912188, JF912189, JF912180, JF912182, JF912185, JF912179, 
JF912184, JF912183, JF912186; for South American genotype 2: TVP17388, JF912181; for 
the West African genotype: AF094612, JX898871, JX898872, AY640589, JX898875, 
JX898874, JX898873, AY572535, AY603338, JX898868, JX898870, JX898876, JX898878, 
JX898880, X898877, JX898869, YFU54798; and for the East African genotype: AY968064, 
AY968065, DQ235229, JN620362. To validate the reference datasets, phylogenetic trees 
were constructed using maximum likelihood (ML) with a general time-reversible model and 
among-site rate variation modeled using a discretized gamma distribution (GTR + 4), which 
was inferred as the best-fitting nucleotide substitution model in jModelTest (83). Trees were 
estimated using RAxML v8 (84) with 100 bootstrap replicates.  All genotype clades are 
supported by bootstrap values of 100%, with the exception of the West-African genotype in 
the env tree, which is supported by a bootstrap score of 99%. 
 
Classification of query sequences using the YFV subtyping tool involves two steps. The 
first step identifies the virus species using the basic local alignment search tool (85) that 
searches the RefSeq NCBI Reference sequence database that contains 7952 viruses reference 
genomes (86). The virus species is identified if the alignment score >400, which is the sum of 
identities minus gaps and mismatches. In addition, the tool also creates a codon alignment 
and identifies polymorphic sites and genetic diversity in the alignment, and aligns the query 
sequence to the NC_002031 curated reference sequence (87).  
The second step involves the reconstruction of a phylogenetic tree with a reference 
dataset using neighbour-joining (Fig. S5). Statistical support for phylogenetic clustering of 
the query strain with the pre-defined reference genotypes using 1,000 bootstrap replicates. A 
query sequence is assigned to a particular genotype if clustering is supported by a bootstrap 
score >70%. The YFV typing tool accepts up to 2,000 sequences per submission and analyses 
each of sequence independently. At the end of the analysis, a phylogenetic tree is created that 
displays all query sequences and the reference dataset. A formatted report, estimated 
phylogenetic tree, and alignments can all be downloaded in multiple formats by the user. 
 
 
Curation of whole-genome sequence datasets 
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We screened the GenBank database for published complete YFV genome sequences 
sampled worldwide using an in-house shell script. Subgenomic gene sequences from vector-
borne flaviviruses typically contain insufficient genetic variation for reliable phylodynamic 
analysis on the time-scale of individual epidemics [e.g. (43, 88, 89)]. Therefore we retrieved 
all publicly available YFV sequences (n=756) from GenBank on 12th June 2018 and retained 
only complete or near complete YFV genomes (>8000 nt; n=200) (90). Sequences were 
collected from the Caribbean (Trinidad), East Africa (Ethiopia, Uganda and Sudan), Central 
Africa (Angola), East Asia (China), West Africa (Senegal, Ivory Coast, Ghana, Nigeria and 
Guinea-Bissau), and South America (Bolivia, Venezuela and Brazil). We then removed i) 
vaccine associated sequences (except the 17DD vaccine and Asibi strain, accession numbers: 
DQ100292 and AY640589), ii) sequences from patents, iii) duplicate entries, and iv) 
unpublished sequences from the Brazilian outbreak. Location and date of collection were 
retrieved from the original GenBank entry or from original publications. After curation, the 
“complete dataset” (n=125) contained complete or near complete YFV genomes sampled 
from 1927 to 2017. Sequences were aligned using MAFFT v.7 (91). Maximum likelihood 
(ML) phylogenetic trees were estimated using RAxML (84) under a GTR + 4 nucleotide 
substitution model, as described previously. ML trees were estimated from i) the “complete 
dataset” described above (n=125) (Fig. S6A), ii) the “SA1 dataset”, a subset of the complete 
dataset containing only South American genotype 1 (SA1) sequences (n=86) (Fig. S6B), and 
the iii) the “outbreak dataset”, a subset of the SA1 dataset containing sequences only from the 
Brazilian outbreak (n=65) (Fig. S6C). For each of these three phylogenies, we conducted 
root-to-tip regressions of sequence sampling date against genetic divergence (92) (Figs. S6A-
C). A preliminary analysis  identified 7 anomalous sequences with low genome coverage 
(<26%), which may represent potential contaminants or mislabelled sequences (92) and were 
therefore excluded from subsequent analyses. All alignments were screened for 
recombination using the Phi-test available in SplitsTree v.4 (93); the null hypothesis of the 
absence of recombination could not be rejected (P<0.05) and lack of recombination was 
confirmed using the RDP4 package (94). The outbreak dataset comprises 65 genome 
isolates, 62 of which were generated by this study, 2 of which were published in (33) and 1 
published in (95) (Fig. S6C and Table S2). 
 
 
Bayesian skygrid with epidemiological covariates 
Time-scaled phylogenetic trees were reconstructed using the Bayesian phylogenetic 
inference framework available in BEAST v1.8.4 (96). We used a probabilistic approach that 
combined sequence substitution over an unknown tree, calibrated to a real time scale using a 
molecular clock model. We used the HKY + 4 nucleotide substitution model and a relaxed 
molecular clock model, with an underlying lognormal distribution of branch rates (97). 
 
For the molecular clock model, we assumed that the outbreak clade exhibited a different 
clock rate to ancestral paraphyletic lineages, as observed in previous epidemics (98) and 
therefore we used a fixed local clock model (27) on the SA1 dataset; Fig. S6B). We also 
computed a Bayesian skygrid model (99) using the outbreak dataset alone (Fig. S6C), for 
which we specified 36 grids (i.e. the approximate number of epidemiological weeks spanned 
by the duration of the phylogeny). Further, we ran a Bayesian skygrid-based generalized 
linear model (40) with a streamlined prior specification in which effective population size 
through time is associated with a single covariate, chosen probabilistically from a set of 
possible covariates, while also accounting for phylogenetic uncertainty. In this analysis we 
investigated the following set of 3 covariates: i) log-linear YFV(H) case counts (dataset A), 
ii) log-linear YFV(NHP) case counts (dataset B) and iii) log-linear CHIKV human case 
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counts (dataset C). Specifically, for each grid point (epidemiological week) we include the 
log-transformed and standardized number of cases as described in the above section entitled 
“Description of epidemiological data from Minas Gerais, Brazil”. The association of each 
particular covariate with the effective population size dynamics of the outbreak is 
summarised by a coefficient and an inclusion probability (Table S8).  
Distributions of the outbreak TMRCA obtained without and with covariates are shown 
in main text Fig. 3c (distributions a and b, respectively). Further, a comparison of the 
TMRCA estimates with and without YFV case count covariates are shown in Fig. S7. 
 
 
Structured coalescent analyses 
Viral lineage transitions among hosts were inferred using a structured coalescent model, 
as implemented in the MultiTypeTree v6.3.0 package (41) for BEAST v2.4.7 (100). The 
analysis was performed on the “outbreak dataset” only (see Fig. S6). The structured 
coalescent model also estimates time-scaled phylogenetic trees and state transition histories. 
It assumes a constant effective population size for each deme (i.e. human vs non-human host 
states, in this study) and asymmetric transition rates between demes. As in the other analyses 
above, we used an uncorrelated relaxed molecular clock model with a lognormal distribution 
prior on the branch rate parameters (97) and a HKY+4 nucleotide substitution model. 
Default priors were used for the nucleotide substitution model. A lognormal prior was placed 
on the molecular clock rate parameter, with mean equal to 0.001 substitutions per site per 
year (in real space) and standard deviation set to 1.  
 
A lognormal prior with mean 0 and standard deviation 4 was used for the effective 
population sizes of demes and transition rates between demes (=host species states). To 
ensure that the phylogenetic timescale is well informed we placed a normally distributed 
prior with mean 0.751 years before the present (and standard deviation 0.18) on the time of 
the most recent common ancestor (TMRCA) of the tree. When estimating transition rates 
between host states, two independent runs of 200 million steps were computed, sampling 
parameters every 20,000 steps. The two chains were combined with LogCombiner, 
discarding 10% of each chain as burn-in and subsampling only half of the remaining states. 
Tracer v1.6.0 (http://tree.bio.ed.ac.uk/software/tracer/) was used to check the MCMC 
analysis for convergence. A maximum clade credibility tree with annotated branches was 
then generated in TreeAnnotator (Fig. 4A; the same tree with detailed taxa information is 
shown in Fig. S8). To recover the number host-switching events through time we counted the 
number of transitions between demes (host states) across monthly intervals for each tree in 
the posterior set of structured coalescent trees (migration histories). This count and its 95% 
HPD interval are shown in Fig. 4C. 
 
To test sensitivity to the TMRCA prior used, the analysis was repeated (i) without a 
prior on the TMRCA and (ii) using a normally distributed prior with mean 0.731 years before 
the present and standard deviation 0.18, which corresponds to the TMRCA inferred under a 
standard skygrid model with covariates (see Fig. 3C). The inferred posterior distributions of 
the transition rates between human and NHP host states are shown in Fig. S9, where it can be 
seen that the TMRCA prior does not significantly affect the estimate transition rate dynamics. 
We also verified that this is the case for the migration histories (data not shown). In addition, 
the rate of host-transition events from NHP to human - our key result - always clearly 
deviates from the prior, whereas the reverse rate (from human to NHP) recovers the prior.  
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Phylogeographic inference in continuous space 
Bayesian continuous phylogeographic analyses were performed on the “outbreak 
dataset” only using the skygrid with covariates as the coalescent tree prior (40). We first 
inferred the best fitting continuous diffusion process by performing (log) marginal likelihood 
estimation using generalized stepping-stone sampling (101) on a range of relaxed random 
walk models, as well as the time-homogeneous Brownian motion process (Table S9). Details 
of the stepping stone sampling approach were as follows: after an initial posterior exploration 
of 10 million iterations, we collected 1000 samples from each of the 51 power distributions, 
distributed according to a Beta(0.3,1.0) distribution and sampling at every 1000th iteration. 
The log marginal likelihood estimates were highly consistent between independent runs in 
BEAST1.8.4 (102). 
 
All the relaxed random walk models strongly outperformed the homogenous Brownian 
diffusion model. A model with Cauchy distributed diffusion rate variation among branches 
yielded the highest Bayes Factor (BF) against the homogenous diffusion model, indicating 
among-branch heterogeneity in branch velocity. The Cauchy model is most strongly 
preferred among all the relaxed random walk models (Table S9).  
 
The Cauchy-distributed phylogeographic model selected above was then used to 
characterise the outbreak’s spatio-temporal epidemic history (44). Posterior distributions 
under the Cauchy models were obtained using Markov chain Monte Carlo (MCMC) 
sampling as implemented in BEAST v 1.8.4 (96). The BEAGLE library v2.1.2 was used to 
accelerate computation (103). MCMC chains were run in triplicate for 250 million 
generations, sampling every 50,000 steps. MCMC performance was inspected for 
convergence and for sufficient sampling using Tracer v.1.6.  
 
To summarise virus diffusion over time and space, 1000 post-burn-in phylogenies 
sampled at regular intervals from the posterior distribution were obtained. The branches of 
these phylogenies were extracted as vectors, each having start and end spatial coordinates, 
and start and end dates (i.e. branch duration) in decimal units (43). The R package 
“seraphim” was used to estimate statistics of spatial dissemination, such as dispersal velocity, 
diffusion coefficients, and evolution of the maximal wavefront distance from epidemic origin 
(104, 105), as well as generating monthly graphical representations of the inferred spatio-
temporal spread process (Movie S1) using the “spreadGraphic” function (106). 
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Fig. S1.  
Number of YF sylvatic cases in Brazil between 1950 and 2018. Data from 1950 to 1980 
are from (107); data from 1980 to 2015 are from Brazilian Ministry of Health (MoH) reports 
(35); data under “2017” are from the Brazilian MoH reports from 1st Dec 2016 to 1st July 
2017 (18); data under “2018” are from 1st July 2017 to 16/05/2018 (109). Federal states (in 
blue): GO=Goiás, MG=Minas Gerais, SP=São Paulo, PA=Pará, MA=Maranhão, BA=Bahia, 
MS=Mato Grosso do Sul, RS=Rio Grande do Sul. Regions (in red): CW=Centre-West, 
SE=South-east, S=South, N=North, S=South. 
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Fig. S2. 
Sensitivity of diagnostics for human YFV (left) and CHIKV (right) samples in Minas 
Gerais. The proportion of samples positive for at least one test (black bars) in each age- and 
sex-class is shown, together with the proportion of positives for each test separately 
(IgM=yellow bars, viral isolation=blue bars, RT-qPCR=red bars).  
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Fig. S3. 
Geographic distribution of CHIK cases in Minas Gerais. The figure shows cases 
confirmed by serology, RT-qPCR, or virus isolation in Minas Gerais from Jan 2015 to 
October 2017 (corresponding to dataset C).  
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Fig. S4. 
Age-sex distribution of reported CHIKV cases in Minas Gerais. The y-axis shows the 
percentage of CHIV cases belonging to each age- and sex-class that were confirmed by at 
least one diagnostic test in Minas Gerais, between Jan 2015 and October 2017 (dataset C). 
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Fig. S5. 
Illustration of the output of the online YFV classification tool. The figure shows the ML 
phylogeny of 6 target sequences analyzed by the tool. The output also provides a link to 
genome coverage and a more detailed report. The reference dataset is colored according to 
genotype. 
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Fig. S6. 
Maximum likelihood (ML) phylogenies and temporal signal of YFV near-complete 
genome sequence datasets. (A) The “complete dataset” (n=125). The figure shows the ML 
phylogeny for this alignment and its corresponding temporal signal (regression between 
sampling dates and genetic divergence). Branches are in nucleotide substitutions per site 
(scale bar). Tips are coloured according to geographic region of sample collection. The 
position of the SA1 genotype is shown to the right of the tree. (B) The “SA1 dataset” (n=86) 
that contains South American genotype 1 sequences only. The position of the outbreak clade 
is shown to the right of the tree. See panel A for further explanation. (C) The “outbreak 
dataset” (n=65). The corresponding regression analysis for this tree is provided in Fig. 3. See 
panel A for further explanation.  
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Fig. S7. 
Combining virus phylogeny and epidemic time series. The left hand column shows 
maximum clade credibility trees (MCCs) generated in BEAST, together with their 
corresponding posterior distributions of the time of most recent common ancestor (TMRCA; 
grey) of the outbreak clade. Thin horizontal red bars indicate uncertainty in estimates of 
divergence times of internal nodes in each tree.  The right hand column shows the 
corresponding Bayesian skygrid effective population size estimate. Black dashed line on the 
left = median estimate, black dashed line on the right = lower 95% highest posterior density 
(HPD) credible interval TMRCA estimate, and blue shaded area = 95% HPD credible 
interval. The top row (A) shows the results obtained using the standard skygrid model whilst 
the bottom row (B) shows the results obtained using skygrid model with covariates (B). 
Addition of the epidemiological time series data in (B) reduces the statistical uncertainty of 
the estimated TMRCA parameter by ~30%.  
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Fig. S8. 
Typed maximum clade credibility tree (corresponding to Fig. 4A). The node labels 
indicate the posterior probability of the most likely host state for each internal node, inferred 
by the MultiTypeTree package (41). This representation does not include information on 
individual transition events between host states. 
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Fig. S9. 
Estimated posterior distributions of host state transition rates of the structured 
coalescent model under different priors. From left to right, (i) using no prior on the 
TMRCA, and (ii) using a normal distribution with mean 0.73 years before the present and 
standard deviation of 0.18. The prior distribution used for the migration rates is shaded with 
dashed red lines.  
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Fig. S10. 
Molecular clock phylogeny of the YFV epidemic in Brazil. This tree includes sequences 
published in studies of the secondary epidemic  Blue taxa = generated by this study; orange 
taxa = generated two separate studies of the secondary epidemic wave of YFV in Brazil (34, 
109). Tree was estimated in BEAST v1.8.4 (96) using a HKY + 4 nucleotide substitution 
model and a relaxed molecular clock model, with an underlying lognormal distribution of 
branch rates (97). 
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Table S1. 
Time-series cross correlation analysis. A, B and C correspond to the datasets A, B and C 
described in the text. Period = the time frame during which the comparison is made. The 
dataset in brackets is fixed during that period, while the other dataset is shifted temporally to 
correct for potential lag. p-value = the p-value of the correlation between the two “auto-
correlated” series, accounting for the time-lag. Time lag = the lag between the two series, 
estimated to the nearest day via linear interpolation. Similar results were obtained when 
datasets D and B, D and C, and B and E were compared (data not shown). 
 
 
 
Comparison A vs B A vs C B vs C 
Period 
1 Aug 2016 to 
1 Oct 2017 (A) 
1 Aug 2016 to 
1 Oct 2017 (A) 
1 Aug 2016 to 
 1 Oct 2017 (A) 
P-value <0.0001 <0.0001 <0.0001 
Cross-correlation 0.971 0.757 0.725 
Time lag 
B is 4 days C is 62 days C is 64 days 
ahead of A behind A behind B 
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Table S2. 
Laboratories involved in YFV genome sequencing. H=Human, NHP=Non-human primate, 
MG = Minas Gerais, BA=Bahia, RJ=Rio Janeiro, ES=Espírito Santo. 
 
 
 
Institution, State 
Sample 
collection 
Sequencing 
Platform 
FUNED, MG  MG MinION 
FIOCRUZ, BA MG, BA MinION 
FIOCRUZ, RJ MG, ES, RJ Ion TorrentTM 
IAL, SP ES MiSeq  
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Table S3. 
Epidemiological data associated with each isolate processed/sequenced in this study. 
ID=Project identifier; Lab=Laboratory where samples were processed/sequenced; Host=Host 
species; State: MG=Minas Gerais, BA=Bahia; ES=Espirito Santo; RJ=Rio de Janeiro; 
Municipality=municipality of residence (unless stated otherwise). Date=Date of sample 
collection; Ct=RT-qPCR Cycle threshold value. “–”=not available. NHP=non-human primate 
of unknown species. *Alouatta spp. suspected. 1=Patient M26 was a resident of São Caetano 
do Sul, São Paulo, whose symptoms began on 30th December 2016. Travel history suggests 
that M26’s infection occurred in Itambacuri municipality, neighboring Teófilo Otóni 
municipality, in Minas Gerais. 2= Patient M123 was from São Paulo and visited Itambacuri, 
Minas Gerais. The patient reported receiving a vaccination, but no vaccination date was 
available. 3=Patient M138 was vaccinated in Jan 2017 and developed symptoms 3 days later. 
4=Patient RJ185 was vaccinated in Jan 2017, 4 days before sample collection.  
 
ID Lab 
Sampl
e 
Host 
Stat
e 
Municipality Date 
C
t 
Se
x 
Age 
Residenc
e 
M5 
FUNE
D 
Liver Alouatta  MG Sta. Rita de Caldas 
15/02/201
7 
11 - - - 
M7 
FUNE
D 
Tissue Cebidae MG Delfinopolis 
14/02/201
7 
6 - - - 
M9 
FUNE
D 
Tissue Alouatta MG Ouro Fino 
15/02/201
7 
11 - - - 
M11 
FUNE
D 
Tissue Cebidae MG Caldas 
13/02/201
7 
6 - - - 
M16 
FUNE
D 
Liver Human MG Caratinga 
09/01/201
7 
17 M 43 Urban 
M17 
FUNE
D 
Liver Human MG Ladainha 
14/01/201
7 
12 M 49 Rural 
M18 
FUNE
D 
Liver Human MG Itambacuri 
21/01/201
7 
15 M 52 Rural 
M25 
FUNE
D 
Liver Human MG Novo Cruzeiro 
25/01/201
7 
13 M 62 Rural 
M26 
FUNE
D 
Liver Human MG Itambacuri 
07/01/201
7 
15 M 62 Rural1 
M35 
FUNE
D 
Liver Human MG Teófilo Otóni 
20/01/201
7 
21 M 45 Rural 
M36 
FUNE
D 
Liver Human MG Novo Cruzeiro 
14/01/201
7 
16 F 55 Rural 
M43 
FUNE
D 
Liver Human MG Pote 
18/01/201
7 
13 M 43 Rural 
M47 
FUNE
D 
Liver Human MG Setubinha 
19/01/201
7 
12 M 40 Urban 
M48 
FUNE
D 
Liver Human MG Ladainha 
07/01/201
7 
17 M 52 Rural 
M51 
FUNE
D 
Liver Human MG Novo Cruzeiro 
18/01/201
7 
18 M 46 Urban 
M58 
FUNE
D 
Liver Human MG Itambacuri 
28/01/201
7 
22 M 53 Rural 
M68 
FUNE
D 
Liver Human MG Ladainha 
28/01/201
7 
20 F 55 Rural 
M73 
FUNE
D 
Liver Cebidae MG Aguanil 
22/02/201
7 
14 - - Urban 
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M78 
FUNE
D 
Liver Callithrix MG Claraval 
20/02/201
7 
12 - - Rural 
M79 
FUNE
D 
Liver Alouatta MG Abre Campo 
17/02/201
7 
11 - - Rural 
M83 
FUNE
D 
Liver Callithrix MG Ladainha 
09/02/201
7 
12 M 
Adul
t 
- 
M94 
FUNE
D 
Liver Human MG Imbe de Minas 
13/01/201
7 
14 M 38 Rural 
M96 
FUNE
D 
Liver Human MG Ladainha 
19/01/201
7 
19 M 56 Urban 
M98 
FUNE
D 
Liver Human MG Teófilo Otóni 
10/01/201
7 
15 M 72 Urban 
M99 
FUNE
D 
Liver Human MG Teófilo Otóni 
21/01/201
7 
10 M 58 Rural 
M100 
FUNE
D 
Liver Human MG Ladainha 
02/01/201
7 
14 M 43 Rural 
M105 
FUNE
D 
Liver Human MG Pie. Caratinga 
12/01/201
7 
17 M 33 Rural 
M107 
FUNE
D 
Liver Human MG Novo Cruzeiro 
30/01/201
7 
9 M 35 Rural 
M123 
FUNE
D 
Serum Human MG Itambacuri 
27/01/201
7 
18 F 47 Rural2 
M138 
FUNE
D 
Serum Human MG St. Barbara Leste 
20/01/201
7 
15 M 50 Rural3 
M164 
FUNE
D 
Serum Human MG Simonesia 
30/01/201
7 
32 F 0 - 
M210 UFMG Liver Callithrix  MG Sabinópolis 
19/01/201
7 
12 F - - 
M211 UFMG Liver Alouatta  MG José Raydan 
13/01/201
7 
9 F - - 
M216 UFMG Liver 
Callicebu
s  
MG Luisburgo 
25/01/201
7 
14 F - - 
M217 UFMG Liver Cebidae  MG Chapada Gaúcha 
25/01/201
7 
11 M - - 
M225 
FioCru
z 
Serum Human MG - 
15/03/200
3 
- - - - 
M226 
FioCru
z 
Serum Human MG - 
15/08/200
3 
- - - - 
M218 
FioCru
z 
- NHP BA Cordeiros 
10/03/201
7 
- - - - 
438 
FioCru
z 
blood NHP ES Domingos Martins 
31/01/201
7 
19 - - - 
460 
FioCru
z 
Liver Human MG Novo Cruzeiro 
30/01/201
7 
16 M 35 Rural 
465 
FioCru
z 
Liver Human MG Itambacuri 
30/01/201
7 
17 M 35 Rural 
480 
FioCru
z 
Liver Human MG Teófilo Otóni 
28/01/201
7 
13 F 47 Rural 
532 
FioCru
z 
Liver Alouatta  MG Coronel Murta 
13/01/201
7 
8 F 
Adul
t 
- 
1536 
FioCru
z 
serum Human ES Vitória 
22/02/201
7 
11 M 31 Urban 
1818 
FioCru
z 
serum Human ES Cariacica 
10/03/201
7 
19 M 65 Urban 
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2109 
FioCru
z 
Liver Alouatta  ES Cariacica 
08/03/201
7 
7 - - - 
2115 
FioCru
z 
Liver Callithrix  ES Cariacica 
09/03/201
7 
11 - - - 
3919 
FioCru
z 
serum Human ES Domingos Martins 
10/04/201
7 
14 M 45 Rural 
4278 
FioCru
z 
Liver Alouatta  RJ Maricá 
17/04/201
7 
11 M 5  
4480 
FioCru
z 
plasma Human RJ Casimiro de Abreu 
22/04/201
7 
19 M 47 Urban 
8 IAL Liver NHP * ES Itarana 
24/01/201
7 
12 - - - 
11 IAL Liver NHP * ES 
Venda N. 
Imigrante 
24/01/201
7 
13 - - - 
RJ14
3 
FioCru
z 
Liver Callithrix MG José Raydan 
24/01/201
7 
10 - 1 - 
RJ14
8 
FioCru
z 
Liver Human MG Teófilo Otóni 
24/01/201
7 
18 M 44 Rural 
RJ15
0 
FioCru
z 
Liver Human MG Teófilo Otóni 
27/01/201
7 
18 M 46 Rural 
RJ15
1 
FioCru
z 
Liver NHP * MG Itamarandiba 
13/01/201
7 
9 - 1 - 
RJ15
3 
FioCru
z 
Liver Callithrix MG Felício dos SAntos 
24/01/201
7 
9 - 1 - 
RJ15
7 
FioCru
z 
Liver Human MG Teófilo Otóni 
05/02/201
7 
17 M 35 Rural 
RJ16
2 
FioCru
z 
Liver Callithrix MG Chapada Gaúcha 
03/02/201
7 
9 - - - 
RJ16
3 
FioCru
z 
Liver Callithrix MG Sacramento 
09/02/201
7 
13 - - - 
RJ16
4 
FioCru
z 
Liver NHP * MG Juatuba 
14/02/201
7 
11 - - - 
RJ16
8 
FioCru
z 
Spleen Alouatta MG 
Bom Jesus do 
Galho 
23/01/201
7 
18 - - - 
RJ17
1 
FioCru
z 
Liver NHP * MG S. Roque de Minas 
03/02/201
7 
9 - - - 
RJ18
5 
FioCru
z 
Serum Human MG 
S. João 
Evangelista 
22/01/201
7 
14 M 39 Rural4 
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Table S4. 
Primer sequences (n=54) for the YFV-500bp MinION sequencing scheme. 
 
>YFV_500_1_LEFT 
GTCTGGTCGTAAAGCTCAGGGA 
>YFV_500_1_RIGHT 
TGGGGCAGTTGTATTCCATGGA 
>YFV_500_2_LEFT 
TCTGAGGACCTTGGGAAAACCT 
>YFV_500_2_RIGHT 
ACCCCCTCAATGAAATCCCTGT 
>YFV_500_3_LEFT 
AACATGACGCAACGAGTTGTCA 
>YFV_500_3_RIGHT 
TGTTCCAATTCTCCTGCTTGGC 
>YFV_500_4_LEFT 
TGCCAAGTTTACCTGTGCCAAA 
>YFV_500_4_RIGHT 
CTTTTGTGACTCGCATTGCACC 
>YFV_500_5_LEFT 
TGGAATTTGAGCCTCCACATGC 
>YFV_500_5_RIGHT 
TCCTTGTGCCACTGGTAAGTCA 
>YFV_500_6_LEFT 
GCCTCCACCAATGATGATGAAGT 
>YFV_500_6_RIGHT 
ACACTTGAGCTCTCTCTTGCCA 
>YFV_500_7_LEFT 
ACAATGTCCATGAGCATGATCCT 
>YFV_500_7_RIGHT 
ACGGACACTCTTTCCTGGACTT 
>YFV_500_8_LEFT 
CAATACGGCTGGAAGACTTGGG 
>YFV_500_8_RIGHT 
GGCAAGCTTCCCTTTTCACCTC 
>YFV_500_9_LEFT 
TCAATTGGGGGTCCAGTTAGCT 
>YFV_500_9_RIGHT 
TCATGAAAGTGCAGTCCAACCG 
>YFV_500_10_LEFT 
GTTGGAGGCATGGTGCTTCTAG 
>YFV_500_10_RIGHT 
GGGGTATGGTCTTCTGCATGGA 
>YFV_500_11_LEFT 
TGACAATGGCTGAGGTGAGACT 
>YFV_500_11_RIGHT 
ATCCCATGGCACCTTCTCTTCA 
>YFV_500_12_LEFT 
TGGGAAGAGGAAGCTGAGATCAG 
>YFV_500_12_RIGHT 
TCTCCATCCCATCTACCCTCCA 
>YFV_500_13_LEFT 
CGAGGGGCCTTTCTCGTTAGAA 
>YFV_500_13_RIGHT 
GTCTTGTTTTCCCAGCTCCAGG 
>YFV_500_14_LEFT 
AACTGAGGTGAAAGAGGAGGGG 
>YFV_500_14_RIGHT 
GGGGTGGCAGTCATCAAGATTG 
>YFV_500_15_LEFT 
ATCATCATGGACGAAGCACATTTTT 
>YFV_500_15_RIGHT 
CCTTCATCCACAAGCACAGGTT 
>YFV_500_16_LEFT 
TCTTGGCCACTGACATAGCTGA 
>YFV_500_16_RIGHT 
CTCAAAGCACCACTTTCGGTCA 
>YFV_500_17_LEFT 
ATGACCAGAGGAGAGTCTTCCG 
>YFV_500_17_RIGHT 
GGCCAGAACAAACAGCATGACT 
>YFV_500_18_LEFT 
TGCTCTTGCACTCTGAGGAAGG 
>YFV_500_18_RIGHT 
GCAGCTCCTGGTTTCAAGTCAA 
>YFV_500_19_LEFT 
AGGCATGCTGGAAAAGACTAAGG 
>YFV_500_19_RIGHT 
TTCTTCTCATAGAGGGCAGGCA 
>YFV_500_20_LEFT 
GCACAGAGGAGGGTGTTTCATG 
>YFV_500_20_RIGHT 
CACGGTCCACTTCCACAATGTC 
>YFV_500_21_LEFT 
AAGATGAAGACTGGACGCAGGG 
>YFV_500_21_RIGHT 
GATGATGGGGACGACTCTCCAA 
>YFV_500_22_LEFT 
TGGGGTGGAACATCATCACCTT 
>YFV_500_22_RIGHT 
TCTGTTTCCACACTGCGTGTTC 
>YFV_500_23_LEFT 
CTGTGAATCAAACATCCCGCCT 
>YFV_500_23_RIGHT 
GGTTCTTTTCTCTGGCCAGGTG 
>YFV_500_24_LEFT 
TGACACCAGAGCAAAGGATCCA 
>YFV_500_24_RIGHT 
CGCATAGAATCCACCACCCTCT 
>YFV_500_25_LEFT 
TGAATGAGGACCACTGGGCATC 
>YFV_500_25_RIGHT 
ATCTCCACTCACTGCCATCCTC 
>YFV_500_26_LEFT 
TGATACACCACCAGCATGTCCA 
>YFV_500_26_RIGHT 
CTTCCCATGAACAGACCACGTG 
>YFV_500_27_LEFT 
CAAGATGAGCTGGTTGGCAGAG 
>YFV_500_27_RIGHT 
CTGCAGATCAGCATCCACAGAG 
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Table S5. 
Statistics for the sequences generated using the MinION sequencer. 
 
Sample Host Ct Total 
Reads 
Mapped 
Reads 
Bases Covered 
>10x 
Bases Covered 
>=25x 
% Reference 
Covered 
M5 NHP 11 35357 35319 10216 10216 99 
M7 NHP 6 29103 29073 10216 10216 99 
M9 NHP 11 16838 16781 10216 10216 99 
M11 NHP 6 13499 13416 10216 10216 99 
M16 Human 17 45277 44706 10216 9946 97 
M17 Human 12 12984 12974 10216 10216 99 
M18 Human 15 30246 27268 10204 9370 91 
M25 Human 13 9477 9463 10216 10214 99 
M26 Human 15 116601 111963 10216 10204 99 
M35 Human 21 35936 28670 9946 9673 94 
M36 Human 16 24004 22049 10216 9358 91 
M43 Human 13 4858 4836 10216 9365 91 
M47 Human 12 130596 130176 10216 10213 99 
M48 Human 17 11516 11119 6460 5767 56 
M51 Human 18 37159 36972 10216 10216 99 
M58 Human 22 45367 45163 10216 10216 99 
M68 Human 20 45925 45642 10216 10209 99 
M73 NHP 14 107280 105827 10216 10216 99 
M78 NHP 12 24353 24190 10216 10216 99 
M79 NHP 11 35816 35449 10216 10216 99 
M83 NHP 12 46097 45590 10216 10216 99 
M94 Human 14 215524 213371 10216 10216 99 
M96 Human 19 22424 20838 8772 5768 56 
M98 Human 15 66026 65498 10216 9673 94 
M99 Human 10 93181 92822 10216 10216 99 
M100 Human 14 148291 147395 10216 10216 99 
M105 Human 17 36169 35955 10216 10216 99 
M107 Human 9 21532 21417 10216 10216 99 
M123 Human 18 31236 30980 10216 10136 98 
M138 Human 15 77337 76703 10216 10216 99 
M164 Human 32 33076 28899 9075 8346 81 
M210 NHP 12 359234 358667 10216 10216 99 
M211 NHP 9 342819 342251 10216 10216 99 
M216 NHP 14 387989 387305 10216 8916 87 
M217 NHP 11 260350 259631 10211 7361 71 
M218 NHP - 70075 69013 10216 10216 99 
M225 NHP - 87647 87506 10216 10216 99 
M226 NHP - 81415 81160 10216 10216 99 
RJ143 NHP 10 733 604 8266 3442 54 
RJ148 Human 18 17853 6546 9541 9539 93 
RJ150 Human 18 26895 25073 9855 9844 96 
RJ151 NHP 9 2919 2809 10170 9764 97 
RJ153 NHP 9 2857 2758 10172 10166 99 
RJ157 Human 17 7531 5025 9258 9256 90 
RJ162 NHP 9 6276 6176 10172 10168 99 
RJ163 NHP 13 4210 4171 10171 9859 99 
RJ164 NHP 11 2563 2549 9851 9403 92 
RJ168 NHP 18 3202 2544 9430 8804 89 
RJ171 NHP 9 1603 1534 10115 8014 85 
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RJ185 Human 14 3369 33555 10171 9717 99 
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Table S6. 
Statistics for the sequences generated using the IonTorrent sequencer. 
 
 
Sample Host Ct 
Total 
Reads 
Mapped 
Reads 
Bases 
Covered 
>1x 
Bases 
Covered 
>=10x 
% 
Reference 
Covered 
438 NHP 19 223937 217572 9958 9957 97 
460 Human 16 44315 41509 9541 8718 81 
465 Human 17 207616 202108 9811 9647 94 
480 Human 13 47989 44951 9950 9922 96 
532 Alouatta 8 283134 277698 10234 9948 97 
1536 Human 11 71865 67197 9951 9721 97 
1818 Human 19 46210 42614 9273 8824 82 
2109 Aloutta 7 324683 315437 10120 10005 97 
2115 Callithrix 11 43913 40994 9950 9467 91 
3919 Human 14 44821 39888 9735 9139 82 
4278 Alouatta 11 44873 41367 9931 9667 97 
4480 Human 19 217496 210440 9951 9950 97 
 
 
 
 
  
 46 
Table S7. 
Statistics for the sequences generated using the MiSeq sequencer. 
 
 
Sample Host Ct Total 
Reads 
Mapped 
Reads 
Bases 
Covered >1x 
Bases Covered 
>=10x 
% Reference 
Covered 
8 NHP 12 429568 1507 9774 5307 96 
11 NHP 13 574990 3120 9995 7754 98 
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Table S8. 
Coalescent generalized linear model results. Inclusion = probability that the predictor was 
included in the model. BF = Bayes factor. cEffect = conditional effect size, which represents 
the estimate of the coefficient conditional on the predictor being included in the model. Both 
the mean and the 95% highest posterior density credible interval (95% HPD) of the 
conditional effect size are reported. YFV(H), YFV(NHP) and CHIKV correspond to the time 
series in epidemiological datasets A to C described above. * HPDs could not be computed for 
CHIKV as the predictor is too infrequently included in the model.  
 
 
Predictor  Inclusion BF cEffect (95% HPD) 
YFV(H) 0.367 1.870 0.959 (0.623, 1.320) 
YFV(NHP) 0.633 4.812 1.081 (0.713, 1.466) 
CHIKV 0.0003 0.0002 0.761 (NA, NA)* 
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Table S9. 
Generalized stepping-stone (GSS) sampling for each of the continuous diffusion models. 
Models are ordered according to their Bayes Factor (BF) score, calculated against the 
Brownian diffusion model (homogeneous diffusion). 
 
 
Model  GSS Bayes Factor 
Homogeneous -16648,01 0.0 
Lognormal -16605,42 42.59 
Cauchy -16580,12 67.89 
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Movie S1. 
Reconstructed spatiotemporal diffusion of the YFV outbreak in Brazil. 
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Sazonal da Febre Amarela Brasil – 2017/2018" 
(http://portalarquivos2.saude.gov.br/images/pdf/2018/maio/18/Informe-FA-26.pdf) 
Informe 26 (Brasília, 2018). 
109. M. M. Gomez et al., Genomic and structural features of the yellow fever virus from the 
2016-2017 Brazilian outbreak. The Journal of General Virology 99, 536-548 (2018). 
 
